GLP-1 drugs associated with 28% reduced prostate cancer risk in meta-analysis | Research

The takeaway

A meta-analysis of five studies found GLP-1 receptor agonist use was associated with a statistically significant 28% reduction in prostate cancer risk (RR 0.72, 95% CI 0.61-0.83) compared to placebo or other diabetes drugs.

28% risk reduction
GLP-1 receptor agonist use was associated with RR 0.72 for prostate cancer across five studies in meta-analysis

What the researchers found

Meta-analysis RR 0.72 (95% CI 0.610-0.832), indicating 28% reduced prostate cancer risk with GLP-1 RA use. Moderate heterogeneity (I²=51%). Consistent results in sensitivity analysis.

Why it matters

Prostate cancer is the most common cancer in men. If GLP-1 drugs truly reduce risk, the millions of men already taking them for diabetes and obesity would receive an important additional benefit, and GLP-1 drugs could potentially be used for cancer chemoprevention.

How the study worked

Systematic review and meta-analysis of PubMed, Embase, and Web of Science through July 2024. Five studies included (RCTs, cohort, case-control, observational). Random effects model. Quality assessed by Newcastle-Ottawa Scale and Cochrane Risk of Bias tool.

What this study cannot tell us

Only five studies available. Moderate heterogeneity (I²=51%). Mostly observational data—cannot prove causation. Confounding by indication (diabetic patients may differ from general population). Mechanism unexplored.

How to read the evidence

Systematic review and meta-analysis of predominantly observational studies. Moderate evidence strength; direction consistent but confounding cannot be excluded.

When this study was published

Published in 2025; literature search through July 2024.

The bigger picture

This adds to growing evidence that GLP-1 drugs may have anti-cancer properties across multiple tumor types. The mechanisms could involve reduced insulin/IGF-1 signaling, anti-inflammatory effects, or direct anti-proliferative actions on cancer cells.

Questions still open

Is the reduced risk due to GLP-1 drug effects or confounding by other diabetes treatments?
What biological mechanism mediates the cancer-protective effect?
Does the protective effect depend on duration or dose of GLP-1 therapy?

Common questions

Do GLP-1 drugs prevent prostate cancer?

This meta-analysis found a significant association between GLP-1 drug use and 28% lower prostate cancer risk, but it cannot prove the drugs directly prevent cancer. The finding is promising but needs confirmation through larger studies and mechanistic research.

Should men take GLP-1 drugs to reduce cancer risk?

Not based on this evidence alone. GLP-1 drugs are approved for diabetes and obesity. The potential cancer risk reduction is an encouraging additional finding, but it should not be the primary reason for prescribing these medications.

Read the original research

Effect of GLP-1 receptor agonists on prostate cancer risk reduction: a systematic review and meta-analysis.

International urology and nephrology, 57(4), 1039-1049

View on PubMed ↗Publisher’s paper ↗

Citation

Sharma, Nikhil; Khatib, Mahalaqua Nazli; Balaraman, Ashok Kumar; Roopashree, R; Kaur, Mandeep; Srivastava, Manish; Barwal, Amit; Prasad, G V Siva; Rajput, Pranchal; Syed, Rukshar; Sharma, Gajendra; Kumar, Sunil; Singh, Mahendra Pratap; Bushi, Ganesh; Chilakam, Nagavalli; Pandey, Sakshi; Brar, Manvinder; Mehta, Rachana; Sah, Sanjit; Gaidhane, Abhay M; Shabil, Muhammed. (2025). Effect of GLP-1 receptor agonists on prostate cancer risk reduction: a systematic review and meta-analysis.. International urology and nephrology, 57(4), 1039-1049. https://doi.org/10.1007/s11255-024-04266-4